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Background: Chronic subdural hematoma is a common neurosurgical condition especially in the aging population.
Burr hole for drainage is an effective treatment, yet recurrence is reported at 8 to 22 % worldwide, and 1-year
mortality rates could be as high as 32 %. Our previous study on the use of dexamethasone as a primary nonsurgical
treatment showed good response in selected group of patients. This study aims to assess the efficacy of
dexamethasone with surgical drainage in the reduction of recurrence requiring reoperation.
Methods: From October 2000 to September 2006, patients with chronic subdural hematoma admitted to the
Prince of Wales Hospital, The Chinese University of Hong Kong, were randomized to surgical drainage with steroid
versus surgical drainage only. The primary endpoint was symptomatic recurrence requiring reoperation.
Results: Two hundred forty-eight patients were recruited and consented for the randomization during the study
period. One hundred twenty-two received both surgery and steroid (the intervention arm) while 126 received
surgery only (the control arm). The recurrence rate requiring reoperation was 6.6 % (8/122) and 13.5 % (17/126),
respectively (p = 0.109). There was no significant difference in complications such as chest infection (p = 0.201) or
wound infection (p = 0.987). Favorable outcome (Glasgow Outcome Score 4–5) was 104/122 (85.2 %) in the
intervention group versus 105/126 (83.3 %) in the control group, respectively (p = 0.811). Based on the recurrence
rate in our study, we generate a potential sample size of at least 594 patients (type I error = 5 %, power = 80 %,
two-sided test) to detect a significant difference.
Conclusions, brief summary, and potential implications: In this prospective pilot phase IIB randomized
controlled study, steroid with surgical drainage had a lower recurrence with reoperation though statistically
insignificant. It was safe with no significant difference in complication rates. This pilot study generates a potential
sample size for a definitive larger double-blinded randomized controlled trial in the future.
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Chronic subdural hematoma is a common neurosurgical
condition especially in the aging population. Annual es-
timated incidence in the general population was 13.5 per
100,000 persons per year, and for those 65 years old or
above, it was 58.1 per 100,000 persons per year [1]. The
number of people older than 65 years is expected to
double by 2050. Burr hole for drainage is an effective
treatment, yet recurrence is reported at 8 to 22 %
worldwide, and 1-year mortality rates could be as
high as 32 % [2]. Our previous study on the use of
dexamethasone as a primary nonsurgical treatment
showed good response in selected group of patients [3].
This study aims to assess the efficacy of dexamethasone
with surgical drainage in the reduction of recurrence
requiring reoperation.
Methods
This is a prospective open labeled randomized controlled
trial. From October 2000 to September 2006, patients with
chronic subdural hematoma admitted to Prince of Wales
Hospital, The Chinese University of Hong Kong, were
recruited. Inclusion criteria include 18 years old or above
and with informed consent. Exclusion criteria are those
who are contraindicated to steroid. This included presence
of sepsis or untreated infection, presence or history of
peptic ulcer or gastrointestinal bleeding, development of
uncontrolled hyperglycemia or poor diabetes control,
development of delirium, history of Cushing’s disease or
history of osteonecrosis. Markwalder chronic subdural
hematoma grading scale (MGS) was performed upon
presentation. Grade 0 (neurologically normal) or grade IV
(comatose with absent motor response to pain stimulus)
patients were excluded. Patients or relatives who refused
to consent were also excluded from the study. The ran-
domization was performed by opening sealed envelops
with the treatment arm designation. The control arm re-
ceived burr holes for drainage only, and it was performed
within 48 h after admission. The intervention arm re-
ceived dexamethasone and surgical drainage. Dexametha-
sone was administered upon admission, with a treatment
regime: dexamethasone 4 mg q6h for 4 days, then 2 mg
tds for 3 days, then 1 mg bd for 3 days with famotidine.
Burr hole for drainage would preferably be performed
on day 2 after randomization, as long as the clinical
condition stable. The primary outcome is recurrence
with reoperation for drainage. It is open-label, and
both surgeons and patients were not blinded to group
assignment.
The assessment parameters included MGS upon pres-
entation before the operation. Plain CT brain scan upon
admission was performed, and maximum thickness of
the chronic subdural hematoma was measured. During
the hospital stay, there was daily clinical assessment ofneurological status. CT brain scan was also performed
on post-operative day 3, 2 months, 4 months, and
6 months. Re-drainage was defined as reoperation per-
formed within 6 months after the first index operation
when there were symptoms with confirmed radiological
recurrence upon the progress CT scan. It was not
considered as a recurrence or re-drainage as there were
no symptoms radiologically on the same site. Any new
hematoma which developed after 6 months were also
considered as a new disease and was not considered as
recurrence or re-drainage in this study. Complications
were recorded including surgical site infection such as
wound infection or empyema. Other general infections
were documented including chest infection or urinary
tract infection. Glasgow outcome scale (GOS) was per-
formed at 6 months for all patients.
Results
Two hundred forty-eight patients were recruited and
consented for the randomization during the study
period. One hundred twenty-two were in the surgery
and steroid group (intervention arm) while 126 were
in the surgery only group (control arm). The back-
ground demographic of age and sex were comparable
Table 1. The presenting MGS were comparable with
no statistically significant difference. The recurrence
rate requiring reoperation was 6.6 % (8/122) and
13.5 % (17/126), respectively (p = 0.109). The post-
operative Glasgow Outcome Scale (GOS) were com-
parable in both groups, in which there was more
good recovery (GOS 5) in the intervention group
(81.1 %) versus the control group (72.2 %) though
statistically not significant. There was more moderate
disability (GOS 4) in the control group (11.1 %) ver-
sus the intervention group (4.10 %), yet it was not
significant. There was no significant difference in com-
plications such as wound infection (p = 0.987), subdural
empyema (p = 0.987), chest infection (p = 0.201), or urin-
ary tract infection (0.987). In the control group, there was
a patient who died of intracranial hemorrhage and one
of chest infection. In the intervention group, there
was a patient who died of chest infection and sub-
dural empyema. Overall, favorable outcome (Glasgow
Outcome Score 4–5) was 85.2 % (104/122) in the inter-
vention group versus 83.3 % (105/126) in the control
group, respectively (p = 0.811). Based on the recurrence
rate in our study, we generate a potential sample size of
at least 594 patients (type I error = 5 %, power = 80 %,
two-sided test).
Discussion
The use of steroid for chronic subdural hematoma dated
back to 1968 [4]. At that time, it was used in conjunc-
ture to bed rest and mannitol. In 1987, steroid was
Table 1 Background demographic, Pre-operative Markwalder Chronic Subdural Hematoma Grading Scale (MGS), Post-operative
Glasgow Outcome Scale (GOS) and Post-operative complications
Surgery only (control arm) Surgery and steroid (intervention arm) All p value
Age 70.8 71.9 71.3
Female 38/126 (30.2 %) 33/122 (27.0 %) 71
Pre-operative plan CT brain scan findings
Right 42/126 (33.3 %) 49/122 (40.2 %) 91 0.325
Left 52/126 (41.3 %) 58/122 (47.5 %) 110 0.387
Bilateral 32/126 (25.4 %) 15/122 (12.3 %) 47 0.013
Thickness 20.3 mm 22 mm 21.1 mm
Pre-operative Markwalder Chronic Subdural Hematoma Grading Scale (MGS)
upon presentation
Grade I 89/126 (70.6 %) 99/122 (81.1 %) 188 0.074
Grade II 34/126 (26.9 %) 20/122 (16.4 %) 54 0.062
Grade III 3/126 (2.38 %) 3/122 (2.46 %) 6 0.709
Re-drainage rate 17/126 (13.5 %) 8/122 (6.56 %) 25 0.109
Post-operative Glasgow Outcome Scale (GOS)
GOS 5 (good recovery) 91/126 (72.2 %) 99/122 (81.1 %) 0.131
GOS 4 (moderate disability) 14/126 (11.1 %) 5/122 (4.10 %) 0.066
GOS 3 (severe disability) 16/126 (12.7 %) 15/122 (12.3 %) 0.924
GOS 2 (vegetative state) 2/126 (1.59 %) 0/122 (0 %) 0.492
GOS 1 (death) 3/126 (2.38 %) 3/122 (2.46 %) 0.709
Post-operative complications
Chest infection 1/126 (0.79 %) 5/122 (4.10 %) 0.201
Post-op fever 1/126 (0.79 %) 1/122 (0.82 %) 0.492
UTI 1/126 (0.79 %) 0/122 (0 %) 0.987
Wound infection 1/126 (0.79 %) 0/122 (0 %) 0.987
Subdural empyema 0/126 (0 %) 1/122 (0.82 %) 0.987
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in 46 patients, in which 83 % were reported as “symp-
tom-free” [5]. In our previous study conducted in 1998,
we first clearly demonstrated the role of steroid as either
a primary nonsurgical treatment or as an adjunct to-
gether with surgical drainage [3]. At the same time, the
use of steroid with drainage versus steroid alone or
drainage alone was compared in our paper, in which the
use of steroid alone could have good outcome in se-
lected group of patients. In another study in 2007, it
even showed that the use of steroid in patients who have
had operation for chronic subdural hematoma would
have a smaller risk of death by threefold (p = 0.006) [6].
However, secondary intervention rate for use of surgery
alone versus surgery and steroid can be up to 26.3 and
27.3 %, respectively, in another study [7]. So far, there is
no agreed standardized treatment regime within neuro-
surgeons on this common neurosurgical condition [8].
Different methods have been proposed in the past to
optimize the treatment outcome of this condition. For
surgical technique, twist drill craniostomy, burr holecraniostomy, and craniotomy had been compared. It con-
cluded that either twist drill or burr hole craniostomy
should be considered as first tier treatment, in which our
center adopted burr hole craniostomy [9]. Earlier studies
did not show differences between craniostomy-irrigation
versus craniostomy-closed system drainage [10, 11]. Site
of drain placement was also explored such as subperios-
teal drain versus subdural drain, which showed compar-
able outcome [12, 13]. Our recent comment on the latest
meta-analysis of the use of subdural drain in chronic
subdural hematoma expressed concern with the result
predominant by one single randomized controlled trial
findings [14, 15, 16]. At the same time, the role of steroid
is continued to be explored.
A systemic review in 2012 on the use of steroid has
concluded that the five observational studies provided class
III evidence that suggests that the use of steroid in treating
chronic subdural hematoma could be as safe as surgery
[17]. However, the meta-analysis published in 2014 con-
cluded that steroid offered no additional benefit to surgery
[18]. There was no statistical difference in mortality or
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the morbidity was hyperglycemia up to 14.8 to 50 % [3, 7].
Infection was up to 9 % [7]. Only two patients were
reported to have gastrointestinal bleeding [4, 7].
Our current study is the first pilot randomized study
in the use of steroid with surgery versus surgery alone.
MGS Grade 0 (neurologically normal) patients were
excluded as they did not require immediate operative
treatment by burr holes. Hence, it was not suitable for
this group of patients to be randomized into either arm
of the study as both proceed with burr hole for drainage,
with or without steroid. MGS grade IV (comatose with
absent motor response to pain stimulus) patients were
also excluded as well. This is because this group of
patients had profound neurological deficit and might not
benefit from operation in the first place. At the same
time, even if they had undergone burr holes, it was
unlikely that steroid would have a significant impact on
their neurological recovery. Furthermore, the aim of the
study is to look into the recurrence, in which the recur-
rence rate in this group of patients might be counter-
intuitively low because of the higher mortality [19].
The dexamethasone regime in this study was based on
the regime in our previous study conducted from Janu-
ary 1998 to December 1999, which was published in
British Journal of Neurosurgery in 2005. Dexamethasone
was tapered in 2 weeks as adjunct to surgery or 3 weeks
as monotherapy [3]. Dexamethasone has the longest
biological half-life of all glucocorticoids (36 to 54 h). Its
potency is seven times higher than prednisolone [20].
Various studies had demonstrated different steroid-
tapering regime either as an adjunct therapy or as a
monotherapy. In general, the duration of the regime is
striking a balance between the efficacy versus the poten-
tial side effects. Surgery is still the mainstay of the treat-
ment, and as an adjunct, the duration was usually
shorter, whereas as a monotherapy, the duration is gener-
ally longer. One used a daily dose of 12 mg and tapered
down 1 mg/day every 3 days [7]. One even used 16 mg
tapering in 8 weeks as monotherapy [5]. In our study, we
tapered down the dexamethasone in a shorter duration,
from our previous regime of 14 days, to the current
10 days. It is interesting to see an even shorter regime in
the latest ongoing randomized controlled trial to assess
the efficacy of dexamethasone as an adjunct on reduction
in the reoperation rate of chronic subdural hematoma
(the DRESH study), in which it is a 6-day dexamethasone
regime (16, 16, 12, 12, 8, and 4 mg/day) [20]. In our study,
with a shorter steroid regime, the post-operative recur-
rence rate was clinically significant though statistically
insignificant. At the same time, complication rates were
comparable within the two groups. We are looking for-
ward to the result of the ongoing double-blinded random-
ized controlled trial [20].Other than dexamethasone, other nonsurgical treat-
ment has been shown to be effective in a preliminary
study as a medical monotherapy for chronic subdural
hematoma. Hematoma was completely resolved in 17 of
the 23 patients (77.3 %) 3 months after the treatment
was initiated [21]. Whether atorvastatin is effective in
reducing surgical recurrence remains to be tested in a
future prospective study.
Conclusions
In this prospective pilot phase IIB randomized controlled
study, steroid with surgical drainage has a lower recur-
rence with reoperation rate (6.6 and 13.5 %, respectively,
p = 0.109). This pilot study generates a potential sample
size for a larger definitive double-blinded randomized
controlled trial in the future.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WSP and TFS were the lead investigators and contributed with DYC to
writing the report. WSP and TFS contributed in data collection. TFS and DYC
contributed in data analysis. DYC contributed in drafting the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank the residents of the Division of Neurosurgery at Prince of Wales
Hospital, Hong Kong, for their help in recruiting patients to the trial and
acquisition of data.
Received: 5 May 2015 Accepted: 26 June 2015
References
1. Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N. Chronic subdural
hematoma in elderly people: present status on Awaji Island and
epidemiological prospect. Neurol Med Chir (Tokyo). 1992;32:207–9.
2. Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in
the elderly: not a benign disease. J Neurosurg. 2011;114:72–6.
3. Sun TFD, Boet R, Poon WS. Non-surgical primary treatment of chronic
subdural haematoma: preliminary results of using dexamethasone.
Br J Neurosurg. 2005;19:327–33.
4. Bender MB, Christoff N. Nonsurgical treatment of subdural hematomas.
Arch Neurol. 1974;31:73–9.
5. Pichert G, Henn V. Conservative therapy of chronic subdural hematomas.
Schweiz Med Wochenschr. 1987;117:1856–62.
6. Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P. Effectiveness of
adjuvant corticosteroid therapy for chronic subdural hematoma:
a retrospective study of 198 cases. Neurochirurgie. 2007;53:477–82.
7. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Rodríguez-Salazar A,
Galacho-Harriero AM, Fernández-Arconada O. Dexamethasone treatment in
chronic subdural haematoma. Neurocirugia (Astur). 2009;20:346–59.
8. Cenic A, Bhandari M, Reddy K. Management of chronic subdural hematoma:
a national survey and literature review. Can J Neurol Sci. 2005;32:501–6.
9. Weigel R. Outcome of contemporary surgery for chronic subdural
haematoma: evidence based review. J Neurol Neurosurg Psychiatry.
2003;74:937–43.
10. Erol FS, Topsakal C, Faik Ozveren M, Kaplan M, Tiftikci MT. Irrigation vs.
closed drainage in the treatment of chronic subdural hematoma. J Clin
Neurosci. 2005;12:261–3.
11. Javadi A, Amirjamshidi A, Aran S, Hosseini SH. A randomized controlled trial
comparing the outcome of burr-hole irrigation with and without drainage
in the treatment of chronic subdural hematoma: a preliminary report. World
Neurosurg. 2011;75:731–6. discussion 620–3.
Chan et al. Chinese Neurosurgical Journal  (2015) 1:2 Page 5 of 512. Bellut D, Woernle CM, Burkhardt JK, Kockro RA, Bertalanffy H, Krayenbühl N.
Subdural drainage versus subperiosteal drainage in burr-hole trepanation
for symptomatic chronic subdural hematomas. World Neurosurg.
2012;77:111–8.
13. Kwan MCL, Sun DTF, Poon WS. Types of postoperative drainage for chronic
subdural hematoma: to do it on the table or under? World Neurosurg.
2012;77:51–2.
14. Chan DYC, Woo PYM, Poon WS. Chronic subdural Haematoma: to drain or
not to drain, this is the question. World Neurosurg. 2014;82:1007–9.
15. Alcalá-Cerra G, Young AMH, Moscote-Salazar LR, Paternina-Caicedo A.
Efficacy and safety of subdural drains after burr-hole evacuation of chronic
subdural hematomas: systematic review and meta-analysis of randomized
controlled trials. World Neurosurg. 2014;82:1148–57.
16. Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P, et al.
Use of drains versus no drains after burr-hole evacuation of chronic subdural
haematoma: a randomised controlled trial. Lancet. 2009;374:1067–73.
17. Berghauser Pont LME, Dirven CMF, Dippel DWJ, Verweij BH, Dammers R.
The role of corticosteroids in the management of chronic subdural
hematoma: a systematic review. Eur J Neurol. 2012;19:1397–403.
18. Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B,
Yarascavitch B, et al. Chronic subdural hematoma management: a systematic
review and meta-analysis of 34,829 patients. Ann Surg. 2014;259:449–57.
19. Dumont TM, Rughani AI, Goeckes T, Tranmer BI. Chronic subdural
hematoma: a sentinel health event. World Neurosurg. 2013;80:889–92.
20. Emich S, Richling B, McCoy MR, Al-Schameri RA, Ling F, Sun L, et al. The
efficacy of dexamethasone on reduction in the reoperation rate of chronic
subdural hematoma—the DRESH study: straightforward study protocol for a
randomized controlled trial. Trials. 2014;15:6.
21. Wang D, Li T, Tian Y, Wang S, Jin C, Wei H, et al. Effects of atorvastatin on
chronic subdural hematoma: a preliminary report from three medical
centers. J Neurol Sci. 2014;336:237–42.Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
